PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Valproic Acid	60-63	glycogen synthase kinase 3 beta	Homo sapiens	126-135	
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Valproic Acid	60-63	glycogen synthase kinase 3 beta	Homo sapiens	271-280	
10037507-8	1999	Consistent with GSK-3beta inhibition, incubation of SH-SY5Y cells with VPA results in a significant time-dependent increase in both cytosolic and nuclear beta-catenin levels.	Valproic Acid	71-74	glycogen synthase kinase 3 beta	Homo sapiens	16-25	
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Valproic Acid	168-171	glycogen synthase kinase 3 beta	Homo sapiens	0-9	
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Valproic Acid	168-171	glycogen synthase kinase 3 beta	Homo sapiens	187-196